SAN CARLOS, Calif.--(BUSINESS WIRE)--Feb. 27, 2006--POINT Biomedical Corp. announced that the New Drug Application (NDA) for CARDIOsphere (PB127) has been accepted for review by the U.S. Food and Drug Administration (FDA). Under PDUFA (Prescription Drug User Fee Act) III, the FDA's goal is to review and act on the NDA by late October of 2006.
